abcdefghijklmn
opqrstuvwxyz
Test Menu
Test Change Details
Allergy & Immunology
Cardiology & Coagulation
Dermatopathology
Endocrinology
Gastroenterology
Genetics
Hepatology
Infectious Disease
Microbiology
Nephrology
Neurology
Oncology
Pathology
Pediatrics
Rheumatology
Toxicology
Urology
Women's Health
16175: JAK2 V617F Mutation, Quantitative, Plasma-Based, Leumeta® Print View
JAK2 Mutation,QN,Leumeta     pg/uL 
Interpretation      

PRIMARY
1 Whole Blood EDTA 5 (4) mL   Refrigerated - 72 Hour(s)/Room Temperature - 72 Hour(s)  
ALTERNATE
  Whole Blood Heparin 5 (4) mL   Refrigerated - 72 Hour(s)/Room Temperature - 72 Hour(s)  

The Jak2 tyrosine kinase (V617F) was detected in most patients (>80%) with polycythemia vera (PV), 30-50% of patients with either essential thrombocythemia (ET) or myelofibrosis. The Quantitative measurement of V617F may be useful for assessing the correlation of tumor load/phenotype; monitoring/predicting the progression or responses of the disease when MPD patients are under therapy.

Follow standard whole blood collection prodecure. Collect 5 mL whole
blood samples in an EDTA tube. Blood samples are shipped at room
temperature or 4 degrees Celcius. Do not freeze whole blood. Record
the draw time and date on the tube. Ship immediately to maintain
sample stability.
`<
Transport Temperature: Room temperature
Setup Schedule
Monday

Reported (Analytical Time)
7 days

CPT Code
81270

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Notes
METHODOLOGY: Polymerase Chain Reaction Sequencing






© 1996 - 2017 Quest Diagnostics Nichols Institute of Valencia
For test information, please call Client Services at 800-421-4449.

San Francisco Web Design & Database